FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3043288847> ?p ?o ?g. }

• W3043288847 endingPage "100142" @default.
• W3043288847 startingPage "100142" @default.
• W3043288847 abstract "Non-alcoholic steatohepatitis (NASH) leads to cirrhosis and is associated with a substantial socioeconomic burden, which, coupled with rising prevalence, is a growing public health challenge. However, there are few real-world data available describing the impact of NASH.The Global Assessment of the Impact of NASH (GAIN) study is a prevalence-based burden of illness study across Europe (France, Germany, Italy, Spain, and the UK) and the USA. Physicians provided demographic, clinical, and economic patient information via an online survey. In total, 3,754 patients found to have NASH on liver biopsy were stratified by fibrosis score and by biomarkers as either early or advanced fibrosis. Per-patient costs were estimated using national unit price data and extrapolated to the population level to calculate the economic burden. Of the patients, 767 (20%) provided information on indirect costs and health-related quality of life using the EuroQOL 5-D (EQ-5D; n = 749) and Chronic Liver Disease Questionnaire - Non-Alcoholic Fatty Liver Disease (CLDQ-NAFLD) (n = 723).Mean EQ-5D and CLDQ-NAFLD index scores were 0.75 and 4.9, respectively. For 2018, the mean total annual per patient cost of NASH was €2,763, €4,917, and €5,509 for direct medical, direct non-medical, and indirect costs, respectively. National per-patient cost was highest in the USA and lowest in France. Costs increased with fibrosis and decompensation, driven by hospitalisation and comorbidities. Indirect costs were driven by work loss.The GAIN study provides real-world data on the direct medical, direct non-medical, and indirect costs associated with NASH, including patient-reported outcomes in Europe and the USA, showing a substantial burden on health services and individuals.There has been little research into the socioeconomic burden associated with non-alcoholic steatohepatitis (NASH). The GAIN study provides real-world data on the direct medical, direct non-medical, and indirect costs associated with NASH, including patient-reported outcomes in five European countries (UK, France, Germany, Spain, and Italy) and the USA. Mean total annual per patient cost of NASH was estimated at €2,763, €4,917, and €5,509 for the direct medical, direct non-medical, and indirect cost categories, respectively." @default.
• W3043288847 created "2020-07-23" @default.
• W3043288847 creator A5002755310 @default.
• W3043288847 creator A5022855981 @default.
• W3043288847 creator A5023914659 @default.
• W3043288847 creator A5035800019 @default.
• W3043288847 creator A5039389628 @default.
• W3043288847 creator A5045248057 @default.
• W3043288847 creator A5045736313 @default.
• W3043288847 creator A5055420426 @default.
• W3043288847 creator A5058541785 @default.
• W3043288847 creator A5059068278 @default.
• W3043288847 creator A5061280469 @default.
• W3043288847 creator A5071529890 @default.
• W3043288847 creator A5072395263 @default.
• W3043288847 creator A5073758794 @default.
• W3043288847 creator A5074007153 @default.
• W3043288847 creator A5089990874 @default.
• W3043288847 creator A5090665219 @default.
• W3043288847 date "2020-10-01" @default.
• W3043288847 modified "2023-10-17" @default.
• W3043288847 title "Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study" @default.
• W3043288847 cites W1433606059 @default.
• W3043288847 cites W1884764810 @default.
• W3043288847 cites W1969295126 @default.
• W3043288847 cites W1981330988 @default.
• W3043288847 cites W2025680761 @default.
• W3043288847 cites W2036047239 @default.
• W3043288847 cites W2046500740 @default.
• W3043288847 cites W2048613643 @default.
• W3043288847 cites W2059613020 @default.
• W3043288847 cites W2059700860 @default.
• W3043288847 cites W2062618014 @default.
• W3043288847 cites W2064700601 @default.
• W3043288847 cites W2100636086 @default.
• W3043288847 cites W2105359426 @default.
• W3043288847 cites W2121509250 @default.
• W3043288847 cites W2158822657 @default.
• W3043288847 cites W2204688218 @default.
• W3043288847 cites W2254967598 @default.
• W3043288847 cites W2264072217 @default.
• W3043288847 cites W2473786944 @default.
• W3043288847 cites W2508708811 @default.
• W3043288847 cites W2580009538 @default.
• W3043288847 cites W2739746122 @default.
• W3043288847 cites W2759997926 @default.
• W3043288847 cites W2777780841 @default.
• W3043288847 cites W2806839461 @default.
• W3043288847 cites W2906315662 @default.
• W3043288847 cites W3143409077 @default.
• W3043288847 cites W8277583 @default.
• W3043288847 cites W986443882 @default.
• W3043288847 doi "https://doi.org/10.1016/j.jhepr.2020.100142" @default.
• W3043288847 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7397699" @default.
• W3043288847 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32775976" @default.
• W3043288847 hasPublicationYear "2020" @default.
• W3043288847 type Work @default.
• W3043288847 sameAs 3043288847 @default.
• W3043288847 citedByCount "47" @default.
• W3043288847 countsByYear W30432888472020 @default.
• W3043288847 countsByYear W30432888472021 @default.
• W3043288847 countsByYear W30432888472022 @default.
• W3043288847 countsByYear W30432888472023 @default.
• W3043288847 crossrefType "journal-article" @default.
• W3043288847 hasAuthorship W3043288847A5002755310 @default.
• W3043288847 hasAuthorship W3043288847A5022855981 @default.
• W3043288847 hasAuthorship W3043288847A5023914659 @default.
• W3043288847 hasAuthorship W3043288847A5035800019 @default.
• W3043288847 hasAuthorship W3043288847A5039389628 @default.
• W3043288847 hasAuthorship W3043288847A5045248057 @default.
• W3043288847 hasAuthorship W3043288847A5045736313 @default.
• W3043288847 hasAuthorship W3043288847A5055420426 @default.
• W3043288847 hasAuthorship W3043288847A5058541785 @default.
• W3043288847 hasAuthorship W3043288847A5059068278 @default.
• W3043288847 hasAuthorship W3043288847A5061280469 @default.
• W3043288847 hasAuthorship W3043288847A5071529890 @default.
• W3043288847 hasAuthorship W3043288847A5072395263 @default.
• W3043288847 hasAuthorship W3043288847A5073758794 @default.
• W3043288847 hasAuthorship W3043288847A5074007153 @default.
• W3043288847 hasAuthorship W3043288847A5089990874 @default.
• W3043288847 hasAuthorship W3043288847A5090665219 @default.
• W3043288847 hasBestOaLocation W30432888471 @default.
• W3043288847 hasConcept C121955636 @default.
• W3043288847 hasConcept C126322002 @default.
• W3043288847 hasConcept C138816342 @default.
• W3043288847 hasConcept C142724271 @default.
• W3043288847 hasConcept C144024400 @default.
• W3043288847 hasConcept C144133560 @default.
• W3043288847 hasConcept C149923435 @default.
• W3043288847 hasConcept C2777214474 @default.
• W3043288847 hasConcept C2777575235 @default.
• W3043288847 hasConcept C2778721985 @default.
• W3043288847 hasConcept C2778772119 @default.
• W3043288847 hasConcept C2779134260 @default.
• W3043288847 hasConcept C2779478299 @default.
• W3043288847 hasConcept C6964187 @default.
• W3043288847 hasConcept C71924100 @default.
• W3043288847 hasConcept C99454951 @default.

• next